Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 17/20 | 0.79 |
| ▸ | RORC | P51449 | 2/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | RORA | P35398 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | RORB | Q92753 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218990 | 0.89 | MLYCD (1.00) | MLYCDRORCNR1H3NR1I2RORA | |
| SCHEMBL2945331 | 0.83 | MLYCD (0.78) | MLYCDRORCNR1H3NR1H2 | |
| SCHEMBL25687502 | 0.82 | MLYCD (0.56) | MLYCDRORC | |
| SCHEMBL2945327 | 0.76 | MLYCD (0.75) | MLYCDNR1H3NR1H2 | |
| SCHEMBL2942014 | 0.76 | MLYCD (0.70) | MLYCDNR1H3NR1H2 | |
| SCHEMBL25687491 | 0.76 | MLYCD (0.56) | MLYCDRORCNR1H3NR1H2 | |
| SCHEMBL6843869 | 0.75 | MLYCD (1.00) | MLYCD | |
| SCHEMBL2944077 | 0.73 | NR1H2 (0.60) | MLYCDRORCNR1H3NR1H2 | |
| SCHEMBL2944434 | 0.73 | MLYCD (0.69) | MLYCDNR1H3NR1H2 | |
| SCHEMBL25686478 | 0.72 | MLYCD (0.45) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4503232-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| JP-2004521113-A | — | — | 2004-07-15 | — | — | JP | claimed |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
| EP-1353662-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-22 | — | — | EP | claimed |
| WO-2002058690-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | MLYCD 6/4885RORC 2163/4885NR1H3 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.